The development of BVDU: An odyssey
Author:
Open Access
- 29 January 2023
- journal article
- review article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 31
Abstract
Brivudin, (( E)-5-(2-bromovinyl)-2’-deoxyuridine (BVDU) can be considered the gold standard for the treatment of varicella-zoster virus (VZV) infections, such as herpes zoster (shingles). It is available for clinical use in most European countries (except for the UK) and over the whole world (except for the US and Canada). Besides VZV its activity spectrum also includes various other herpesviruses, such as herpes simplex virus type 1 (HSV-1). Its activity against VZV and HSV-1 depends on phosphorylation by the virus-encoded thymidine kinase (TK). In its active form (BVDU TP or BVDU 5’-triphosphate), it can act as both substrate and inhibitor of the viral (i.e., HSV-1) DNA polymerase. It has proven to be effective against herpes zoster, including post-herpetic neuralgia (PHN). It is contra-indicated in patients concomitantly treated by 5-fluorouracil (FU), since its degradation product, ( E)-5-(2-bromovinyl)uracil, is inhibitory to the catabolism of FU, which may enhance the toxicity of the latter. A new compound, the bicyclic nucleoside analogue (BCNA) Cf-1743, has been described, which is a more potent inhibitor of VZV replication than BVDU and which does not interfere with the catabolism of FU. It is applicable orally, as its 5’-valine ester FV-100 (Fermavir), but has not (yet) been marketed for clinical use.Keywords
This publication has 13 references indexed in Scilit:
- Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double‐blind, multinational studyJournal of the European Academy of Dermatology and Venereology, 2004
- Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zosterBiochemical Pharmacology, 2004
- 4. Internationale Konferenz über Varizellen, Herpes zoster und postherpetische Neuralgien (PHN)Die Dermatologie, 2002
- Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: A randomized double‐blind trialJournal of Medical Virology, 1995
- Regeneration of the antivirel drug(E)-5-(2-bromovinyl)-2′ -deoxyuridinein vivoNucleic Acids Research, 1984
- The antiviral spectrum of (E)-5-(2-bromovinyl)-2 '-deoxyuridineJournal of Antimicrobial Chemotherapy, 1984
- Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.BMJ, 1980
- (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.Proceedings of the National Academy of Sciences, 1979
- 9-(2-Hydroxyethoxymethyl)guanine activity against viruses of the herpes groupNature, 1978
- Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanineProceedings of the National Academy of Sciences, 1977